JP2013523179A5 - - Google Patents

Download PDF

Info

Publication number
JP2013523179A5
JP2013523179A5 JP2013505069A JP2013505069A JP2013523179A5 JP 2013523179 A5 JP2013523179 A5 JP 2013523179A5 JP 2013505069 A JP2013505069 A JP 2013505069A JP 2013505069 A JP2013505069 A JP 2013505069A JP 2013523179 A5 JP2013523179 A5 JP 2013523179A5
Authority
JP
Japan
Prior art keywords
fniii
comprises seq
scaffold
multimeric
multimeric scaffold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013505069A
Other languages
English (en)
Other versions
JP2013523179A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/032184 external-priority patent/WO2011130324A1/en
Publication of JP2013523179A publication Critical patent/JP2013523179A/ja
Publication of JP2013523179A5 publication Critical patent/JP2013523179A5/ja
Pending legal-status Critical Current

Links

Claims (18)

  1. 1つ以上の目的のFnIIIドメイン(FOI)に由来する2つのフィブロネクチンIII型(FnIII)単量体足場を含んでいる組み換え多量体足場であって、ここで
    (a)各々のFnIII単量体足場は、AB、BC、CD、DE、EF、およびFGと命名された6つのループ領域に連結された、A、B、C、D、E、F、およびGと命名された7つのβ鎖を含んでおり、
    (b)前記FnIII単量体足場は、直列して接続され、ここで前記単量体のうちの少なくとも2つは、天然には存在しない分子内ジスルフィド結合を含み、
    (c)前記組み換え多量体足場は、少なくとも1つの標的に対して特異的に結合し、かつ
    (d)前記標的に対する作用は、同族のFnIII単量体足場の作用よりも改善されている、多量体足場。
  2. 前記多量体足場が、3、4、5、6、7、または8個のFnIII単量体足場を含む、請求項1に記載の多量体足場。
  3. 少なくとも2つのFnIII単量体足場が、リンカーによって接続される、請求項1または2に記載の多量体足場。
  4. 少なくとも2つのFnIII単量体足場が、FnIII単量体足場の間にリンカーを割り込むことなく直接接続される、請求項1または2に記載の多量体足場。
  5. 前記FnIII単量体足場のうちの少なくとも1つが異種部分に融合されている、請求項1〜4のいずれか1項に記載の多量体足場。
  6. 少なくとも2つのFnIII単量体足場が異なる、請求項1〜5のいずれか1項に記載の多量体足場。
  7. 各々のβ鎖が、目的のFnIIIドメイン(FOI)の同種のβ鎖に対する少なくとも50%の相同性を有し、かつ少なくとも1つのループは、FOI中の同種のループの非天然変異体である、請求項1〜6のいずれか1項に記載の多量体足場。
  8. 前記FOIが、配列番号1〜4および14のいずれか1つからなる群より選択される配列を含む、請求項1〜7のいずれか1項に記載の多量体足場。
  9. 少なくとも1つのFnIII単量体足場のβ鎖が、配列番号1、4または14中の同族のβ鎖に対し少なくとも90%の配列同一性を有する、請求項1〜8のいずれか1項に記載の多量体足場。
  10. 少なくとも1つのFnIII単量体足場について、Aβ鎖が、配列番号41または42を含み、Bβ鎖が、配列番号43を含み、Cβ鎖が配列番号45または131を含み、Dβ鎖が配列番号46を含み、Eβ鎖が配列番号47を含み、Fβ鎖が配列番号49、50または51を含み、かつGβ鎖が配列番号52または53を含む、請求項1〜9のいずれか1項に記載の多量体足場。
  11. 各々のFnIII足場が標的に結合し、さらに少なくとも1つのFnIII単量体足場が以下のアミノ酸配列を含み:
    IEV(XABALITW(XBCCELXYGI(XCDTTIDL(XDEYSI(XEFYEVSLIC(XFGKETFTT、または
    IEV(XABALITW(XBCIELXYGI(XCDTTIDL(XDEYSI(XEFYCVSLIS(XFGKECFTT、または
    IEV(XABALITW(XBCCELXYGI(XCDTTIDL(XDEYSI(XEFYCVSLIC(XFGKECFTT、
    ここでXAB、XBC、XCD、XDE、XEF、およびXFGは、それぞれAB、BC、CD、DE、EF、およびFGのループに存在するアミノ酸残基を表し、Xは、アミノ酸残基AまたはTを表し、かつここでループの長さn= 2〜26である、請求項1〜6のいずれか1項に記載の多量体足場。
  12. ABループが、配列番号35を含み、CDループが配列番号37を含み、かつEFループが配列番号39を含む、請求項1〜11のいずれか1項に記載の多量体足場。
  13. BCループが、配列番号36を含み、DEループが配列番号11を含み、かつFGループが配列番号40を含む、請求項1〜11のいずれか1項に記載の多量体足場。
  14. 請求項1〜13のいずれか1項に記載の多量体足場をコードする単離された核酸分子。
  15. 請求項14に記載の核酸に対して作動可能に連結された発現ベクター。
  16. 請求項15に記載の発現ベクターを含む宿主細胞。
  17. 前記多量体足場が発現される条件下で、請求項15に記載のベクターを含む宿主細胞を培養することを含む、組み換え多量体足場を産生する方法。
  18. 薬学的に許容される賦形剤中に請求項1〜13のいずれか1項に記載の組み換え多量体足場を含む組成物。
JP2013505069A 2010-04-13 2011-04-12 フィブロネクチンタイプiiiドメインに基づく多量体足場 Pending JP2013523179A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32370810P 2010-04-13 2010-04-13
US61/323,708 2010-04-13
PCT/US2011/032184 WO2011130324A1 (en) 2010-04-13 2011-04-12 Fibronectin type iii domain-based multimeric scaffolds

Publications (2)

Publication Number Publication Date
JP2013523179A JP2013523179A (ja) 2013-06-17
JP2013523179A5 true JP2013523179A5 (ja) 2014-05-29

Family

ID=44799000

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013505070A Active JP6041799B2 (ja) 2010-04-13 2011-04-12 Trailr2特異的多量体足場
JP2013505069A Pending JP2013523179A (ja) 2010-04-13 2011-04-12 フィブロネクチンタイプiiiドメインに基づく多量体足場

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013505070A Active JP6041799B2 (ja) 2010-04-13 2011-04-12 Trailr2特異的多量体足場

Country Status (13)

Country Link
US (2) US9212231B2 (ja)
EP (2) EP2560684A4 (ja)
JP (2) JP6041799B2 (ja)
KR (2) KR101747991B1 (ja)
CN (2) CN102906112B (ja)
AU (2) AU2011240620A1 (ja)
BR (1) BR112012026003B1 (ja)
CA (2) CA2795325A1 (ja)
ES (1) ES2755398T3 (ja)
MX (1) MX341119B (ja)
RU (1) RU2628699C2 (ja)
SG (2) SG184185A1 (ja)
WO (2) WO2011130324A1 (ja)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004296376B2 (en) 2003-12-05 2010-03-04 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
BRPI0719597A2 (pt) 2006-11-22 2013-12-17 Adnexus A Bristol Myers Squibb R & D Company Produtos terapêuticos objetivados baseados em proteínas manipuladas para receptores de quinases de tirosina, incluindo igf-ir
WO2009102421A2 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之egfr/igfir結合分子
WO2011130324A1 (en) * 2010-04-13 2011-10-20 Medimmune, Llc Fibronectin type iii domain-based multimeric scaffolds
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
US9562089B2 (en) 2010-05-26 2017-02-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
PT2697257T (pt) 2011-04-13 2016-12-28 Bristol Myers Squibb Co Proteínas de fusão fc compreendendo novos ligantes ou arranjos
EP2709669A1 (en) 2011-05-17 2014-03-26 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
EP3318880B1 (en) 2011-05-17 2020-12-16 Bristol-Myers Squibb Company Improved methods for the selection of binding proteins
HUE051439T2 (hu) 2011-10-11 2021-03-01 Viela Bio Inc CD40L-re specifikus, TN3-eredetû állványok és alkalmazásuk
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
JP2014533249A (ja) 2011-11-07 2014-12-11 メディミューン,エルエルシー 多重特異性を持つ多価結合タンパク質およびその使用
LT2776460T (lt) 2011-11-08 2018-09-10 Umc Utrecht Holding B.V. Sulietas baltymas, apimantis interleukiną-4 ir interleukiną-10
CN104768969B (zh) 2012-09-13 2021-04-16 百时美施贵宝公司 结合至肌生成抑制素的基于纤连蛋白的支架结构域蛋白
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
EP3406629B1 (en) 2013-02-06 2020-06-24 Bristol-Myers Squibb Company Fibronectin type iii domain proteins with enhanced solubility
US10065987B2 (en) 2013-02-12 2018-09-04 Bristol-Myers Squibb Company High pH protein refolding methods
WO2014126871A1 (en) 2013-02-12 2014-08-21 Bristol-Myers Squibb Company Tangential flow filtration based protein refolding methods
EP2968587A2 (en) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
US20160067337A1 (en) 2013-03-14 2016-03-10 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
EA035745B1 (ru) 2013-10-14 2020-08-05 Янссен Байотек, Инк. Связующие молекулы на основе домена фибронектина типа iii с внедренными остатками цистеина
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
EP3647322B1 (en) 2014-03-20 2021-10-20 Bristol-Myers Squibb Company Stabilized fibronectin based scaffold molecules
MX2016011580A (es) 2014-03-20 2016-11-29 Bristol Myers Squibb Co Dominios de fibronectina tipo iii que se unen a albumina de suero.
WO2015148269A2 (en) * 2014-03-24 2015-10-01 Medimmune, Llc Stabilized tnfn3 scaffold proteins
NO2776305T3 (ja) 2014-04-23 2018-01-27
CN106573961B (zh) * 2014-06-20 2022-01-04 豪夫迈·罗氏有限公司 基于chagasin的支架组合物、方法和应用
CA2962783A1 (en) 2014-10-01 2016-04-07 Medimmune, Llc Method of conjugating a polypeptide
CN107207379B (zh) 2014-11-25 2021-08-10 百时美施贵宝公司 用于生物制品的18f-放射性标记的方法和组合物
BR112017019401A2 (pt) 2015-03-12 2018-05-02 Medimmune, Llc método de purificação de proteínas de fusão de albumina
US10385115B2 (en) 2015-03-26 2019-08-20 Duke University Fibronectin type III domain-based fusion proteins
JP7019423B2 (ja) 2015-05-06 2022-02-15 ヤンセン バイオテツク,インコーポレーテツド 前立腺特異的膜抗原(psma)二重特異性結合剤及びその使用
MX2018001511A (es) 2015-08-04 2018-08-01 Univ Duke Polimeros furtivos desordenados de forma intrinseca codificados geneticamente para suministro y metodos para usar los mismos.
WO2017048709A1 (en) 2015-09-14 2017-03-23 Arizona Board Of Regents On Behalf Of Arizona State University Generating recominant affinity reagents with arrayed targets
EP3708580B1 (en) 2015-09-23 2023-11-01 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type iii domains
ES2809125T3 (es) * 2015-09-23 2021-03-03 Bristol Myers Squibb Co Moléculas de armazón a base de fibronectina de unión a glipicano-3
KR20180100302A (ko) * 2015-10-23 2018-09-10 우니베르지태트 트벤테 인테그린 결합 펩티드 및 그의 용도
WO2017106627A1 (en) 2015-12-17 2017-06-22 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
WO2017177148A1 (en) 2016-04-07 2017-10-12 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
CN105802970A (zh) * 2016-05-30 2016-07-27 东北师范大学 靶向沉默Gβ1的shRNA
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
EA201990067A1 (ru) 2016-06-21 2019-07-31 Янссен Байотек, Инк. Цистеин-модифицированные связывающие молекулы на основе домена фибронектина iii типа
CN109890833A (zh) 2016-09-14 2019-06-14 杜克大学 用于递送亲水性药物的基于三嵌段多肽的纳米粒子
US11155584B2 (en) 2016-09-23 2021-10-26 Duke University Unstructured non-repetitive polypeptides having LCST behavior
WO2018111978A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
US10626165B2 (en) 2016-12-14 2020-04-21 Janssen Biotech, Inc. CD8a-binding fibronectin type III domains
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
US10787499B2 (en) * 2017-02-13 2020-09-29 Regents Of The University Of Minnesota EpCAM targeted polypeptides, conjugates thereof, and methods of use thereof
US11554097B2 (en) 2017-05-15 2023-01-17 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
US11680083B2 (en) 2017-06-30 2023-06-20 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
US11491206B1 (en) 2018-02-13 2022-11-08 Duke University Compositions and methods for the treatment of trail-resistant cancer
WO2019165017A1 (en) * 2018-02-23 2019-08-29 The University Of Chicago Methods and composition involving thermophilic fibronectin type iii (fn3) monobodies
CA3098420A1 (en) 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
CN110724198B (zh) * 2018-07-17 2023-05-26 上海一宸医药科技有限公司 长效纤连蛋白iii型结构域融合蛋白
WO2020028806A1 (en) 2018-08-02 2020-02-06 Duke University Dual agonist fusion proteins
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
EP3715376A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of myasthenia gravis
WO2020212602A1 (en) 2019-04-19 2020-10-22 Synerkine Pharma B.V. Therapeutic crosslinking of cytokine receptors
EP3972993A1 (en) 2019-05-21 2022-03-30 Novartis AG Variant cd58 domains and uses thereof
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
CA3140142A1 (en) 2019-05-21 2020-11-26 Novartis Ag Trispecific binding molecules against bcma and uses thereof
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
WO2021009692A1 (en) 2019-07-15 2021-01-21 Medimmune Limited Tripartite systems for protein dimerization and methods of use
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
US11628222B2 (en) 2019-10-14 2023-04-18 Aro Biotherapeutics Company CD71 binding fibronectin type III domains
CN111217903B (zh) * 2020-02-25 2022-11-15 芜湖天明生物技术有限公司 一种重组人纤连蛋白ⅲ1-c及其制备方法和应用
JP2023515633A (ja) 2020-02-28 2023-04-13 ブリストル-マイヤーズ スクイブ カンパニー 放射性標識されたフィブロネクチンに基づく足場および抗体ならびにそのセラノスティクス的使用
CN116249549A (zh) 2020-03-27 2023-06-09 诺华股份有限公司 用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
CN111944204B (zh) * 2020-07-24 2022-03-08 南京理工大学 一种Fe3O4磁性细菌纤维素及其制备方法
TW202228784A (zh) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗peg抗體的化合物
US20230355784A1 (en) 2020-09-23 2023-11-09 Ablevia Biotech Gmbh Compound for the prevention or treatment of autoantibody-mediated conditions
US20230381334A1 (en) 2020-09-23 2023-11-30 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
JP2023542390A (ja) 2020-09-23 2023-10-06 アブレヴィア バイオテック ゲーエムベーハー ウイルスベクターの有効性を増強するための化合物
AU2021347582A1 (en) 2020-09-23 2023-05-18 Ablevia Biotech Gmbh Compound for increasing the efficacy of factor viii replacement therapy
CN116710143A (zh) 2020-09-24 2023-09-05 艾柏力维亚生技有限公司 用于预防或治疗重症肌无力的化合物
KR20230104651A (ko) 2020-11-06 2023-07-10 노파르티스 아게 Cd19 결합 분자 및 이의 용도
EP4240494A1 (en) 2020-11-06 2023-09-13 Novartis AG Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
WO2023180502A1 (en) 2022-03-24 2023-09-28 Ablevia Biotech Gmbh Compound for increasing efficacy of oncolytic viruses
KR102459313B1 (ko) * 2022-04-11 2022-10-26 주식회사 대영방재산업 내구성이 개선된 소방용 수격 흡수기

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996008513A1 (en) 1994-09-16 1996-03-21 The Scripps Research Institute Cytotactin derivatives that stimulate attachment and neurite outgrowth, and methods of making and using same
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
AU731758B2 (en) 1998-07-08 2001-04-05 Mitsui Chemicals, Inc. Method for secretory production of human growth hormone
CN1183160C (zh) * 1998-08-28 2005-01-05 基因技术股份有限公司 人抗因子IX/IXa抗体
EP2154535A1 (en) 1998-12-10 2010-02-17 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
ES2564161T3 (es) * 2000-07-11 2016-03-18 Research Corporation Technologies, Inc Polipéptidos de anticuerpos artificiales
JP2004526419A (ja) 2000-10-16 2004-09-02 フィロス インク. 抗体模倣物および他の結合タンパク質のためのタンパク質骨格
EP2339017A3 (en) 2002-03-29 2011-10-12 Genencor International, Inc. Enhanced protein expression in bacillus
WO2003104418A2 (en) 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Reconstituted polypeptides
CA2489348A1 (en) 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
AU2004296376B2 (en) 2003-12-05 2010-03-04 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
JPWO2005056605A1 (ja) 2003-12-12 2007-12-06 中外製薬株式会社 3量体以上の受容体を認識する改変抗体
GB0416651D0 (en) 2004-07-26 2004-08-25 Proteo Target Aps Polypeptide
UA97096C2 (ru) * 2005-08-31 2012-01-10 Емджен Інк. Выделенное антитело, которое специфически связывает рецептор-2 trail (tr-2)
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
BRPI0621413A2 (pt) 2006-02-13 2011-12-06 Agency Science Tech & Res método de processamento de uma amostra biológica e/ou quìmica
CN101074261A (zh) * 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
WO2008031098A1 (en) 2006-09-09 2008-03-13 The University Of Chicago Binary amino acid libraries for fibronectin type iii polypeptide monobodies
BRPI0719597A2 (pt) 2006-11-22 2013-12-17 Adnexus A Bristol Myers Squibb R & D Company Produtos terapêuticos objetivados baseados em proteínas manipuladas para receptores de quinases de tirosina, incluindo igf-ir
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
AU2008287426B2 (en) 2007-08-10 2014-06-26 Protelica, Inc. Universal fibronectin type III binding-domain libraries
CA2704229C (en) * 2007-10-31 2019-05-07 Medimmune, Llc Protein scaffolds comprising seven beta strand domains and six loop regions
US20100322930A1 (en) 2007-12-27 2010-12-23 Frank Kolbinger Fibronectin-based binding molecules and their use
WO2009133208A1 (en) 2008-05-02 2009-11-05 Novartis Ag Improved fibronectin-based binding molecules and uses thereof
JP2011520961A (ja) * 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
US20100105620A1 (en) * 2008-10-10 2010-04-29 Anaphore, Inc. Polypeptides that bind Trail-R1 and Trail-R2
PL2356269T3 (pl) 2008-10-31 2016-12-30 Kompozycje białek rusztowania oparte na domenie fibronektyny typu III, sposoby i zastosowania
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之egfr/igfir結合分子
CN102596992B (zh) 2009-02-12 2015-09-09 詹森生物科技公司 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
EP2464663A4 (en) 2009-08-13 2013-05-29 Massachusetts Inst Technology RECOMBINANT PROTEINS COMPRISING MUTANT DOMAINS OF FIBRONECTIN
WO2011130324A1 (en) * 2010-04-13 2011-10-20 Medimmune, Llc Fibronectin type iii domain-based multimeric scaffolds

Similar Documents

Publication Publication Date Title
JP2013523179A5 (ja)
JP2010273685A5 (ja)
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
JP2013048638A5 (ja)
GB201206559D0 (en) Polypeptide
JP2010518833A5 (ja)
WO2014202616A3 (en) Rasamsonia gene and use thereof
JP2011504721A5 (ja)
JP2015514423A5 (ja)
MX2012015142A (es) Polipeptidos que tiene actividad beta-glucosidasa y usos del mismo.
JP2011177189A5 (ja)
JP2012126742A5 (ja)
WO2009058285A3 (en) PORCINE DC-SIGN, ICAM-3 AND LSECtin AND USES THEREOF
MY160897A (en) Polypeptide having or assisting in carbohydrate material degrading activity and uses thereof
JP2011087580A5 (ja)
JP2011514139A5 (ja)
JP2012115277A5 (ja)
RU2015112625A (ru) Пептид, применение пептида для лечения сердечно-сосудистых заболеваний, нуклеотидная последовательность, вектор экспрессии, хозяйская клетка, фармацевтическая композиция
WO2014202622A3 (en) Rasamsonia gene and use thereof
PH12015500771A1 (en) Novel fc gamma receptor iib variants
WO2014097113A3 (en) Production of therapeutic proteins in genetically modified mammalian cells
JP2011521902A5 (ja)
JP2018527404A5 (ja)
JP2017503505A5 (ja)
JP2011139704A5 (ja)